• Sonoma Orthopedics

  Participated · Equity · Sep 2025

  Sonoma Orthopedic Products, founded in 2005 in Santa Rosa, has developed two implant devices for repairing fractures of the wrist and collarbone. The devices are implanted inside the bone by an orthopedic surgeon using minimally-invasive techniques. The company says the approach results in less pain and better healing. Sonoma disclosed a new $1.5 million venture funding round in a filing with federal securities regulators. To date the startup has raised more than $25 million, including a $12 million funding round in 2009. Named investors include EDF Ventures, Asset Management Co., Split Rock Partners and MedVenture Associates. Sonoma develops and manufactures orthopedic implants for wrist, ankle, and collarbone fractures. Its patented WaviBody® and ActivLoc® technologies are used in least-invasive surgical procedures to provide fixation for fractures at the core of the bone. The implants are inserted in a canal in the center of the bone, require much smaller incisions with minimal tissue damage, and have no prominence outside the bone. The company intends to use the funds to receive FDA clearance on its new ankle implant, launch it, and scale commercially. Sonoma received $12M in funding from First Analysis, which also placed Tracy Marshbanks on the company’s board. Founded in 2005 and based in Santa Rosa, California, and outside Chicago, the company focuses on minimally invasive fracture fixation solutions. Sonoma Orthopedic Products develops and commercializes least invasive, fracture‑specific implant systems using proprietary technology for orthopedic trauma. The company is led by President and CEO Glen Coleman and was founded by COO Charles Nelson. It intends to use recent funding to launch new products, expand its U.S. sales network, and support key clinical trials. Sonoma also plans to use proceeds to acquire certain key assets of NovaLign Orthopaedics, Inc. In conjunction with the financing, Dr. Walter Lin of Ascension Health Ventures joined Sonoma’s board of directors. The company is based in Santa Rosa, California. Sonoma Orthopedic, based in Santa Rosa, Calif., develops the WaviBody, a flexible device inserted into a fractured bone that then becomes rigid to set breaks anatomically. The company aims to commercialize its first two products, positioning the WaviBody as an alternative to casts, braces and bone plates. Sonoma is currently testing the WaviBody on 50 patients with wrist fractures to evaluate whether they heal faster using the device. Wrist and clavicle fractures have proved problematic because existing treatments can be unwieldy or fail to heal injuries quickly or correctly; Sonoma targets those shortcomings. Financially, the company has raised $25 million to date, including the most recent $12 million round. Sonoma says it has enough runway to last through 2011. Sonoma Orthopedics is a stealthy spinal-device maker based in Santa Rosa, Calif. The company is developing devices that repair or reinforce bones from the inside. It is operating under a stealth profile while advancing those spinal repair technologies. Financially, Sonoma raised at least $10 million in a second funding round. MedVenture Associates led that round, joined by existing investors EDF Ventures, Asset Management, Halo Fund and Angel's Forum. The company previously raised $3 million in a first round last April.

• Spinal Modulation

  Participated · Series D · Jun 2011

  Spinal Modulation’s core product is the Axium Neurostimulator System, which stimulates the dorsal root ganglion (DRG) to provide targeted spinal cord stimulation for chronic, intractable pain, particularly in lower extremities and other hard-to-treat areas. The system’s leads are placed at the DRG and the therapy reportedly uses approximately 95 percent less power than traditional SCS systems. Axium received European CE Mark approval in November 2011 but is not approved for use in the United States. The company has an FDA investigational device exemption (IDE) and anticipated beginning U.S. enrollment in the second half of the year. Spinal Modulation is privately held and based in Menlo Park, CA, and lists Johnson & Johnson Development Corporation, Medtronic, Kleiner Perkins Caufield & Byers, De Novo Ventures, MedVenture Associates, and DFJ InCube Ventures as backers. Clinical evidence and peer-reviewed publications supporting the DRG approach are noted in the announcement. Spinal Modulation is an early-stage medical device company developing a fully implantable spinal cord stimulator system for the treatment of chronic pain. The company has completed development of its first fully implantable spinal cord stimulation system and has initiated international clinical studies. It announced a $30 million Series D financing to support clinical trials and near-term commercialization activities. Proceeds from the financing will be used to conduct clinical trials in the United States and internationally. The company plans to commence commercialization outside the United States in the near future. Headquartered in Menlo Park, California, Spinal Modulation is privately held and backed by strategic and venture investors including Medtronic and several venture firms. Spinal Modulation is a Menlo Park, CA-based medical device company developing next-generation spinal cord stimulator systems. The company's core product is a spinal cord stimulator intended to treat patients suffering from chronic intractable pain. The recently completed financing will support further development of that next-generation system. The company completed a $27.4M Series C financing to fund product advancement. Investors in the round include Johnson & Johnson Development Corporation alongside existing and new venture backers. No operating metrics or revenues were disclosed in the article.

• PolyRemedy

  Participated · Series C · Jun 2011

  PolyRemedy is a provider of personalized wound care systems based in Boston, MA and Mountain View, CA. Its core product, the Personalized Woundcare System™ (PWS), enables clinicians to document care through web-based assessment tools, order personalized wound dressings, and gain visibility into wound care data. The company also produces proprietary PolyFIT™ Antimicrobial Dressings. PolyRemedy plans to enhance PWS mobile software assessment tools and advanced analytics, increase manufacturing capacity for PolyFIT dressings, and expand its sales and marketing team. The company recently closed a $20M Series C financing to support commercialization and these product and commercial initiatives. Mark Carbeau serves as President and CEO, and Cameron McKennitt joined as Chief Commercial Officer to lead sales and marketing.

• Pulmonx

  Participated · Equity · Feb 2010

  Pulmonx is a commercial-stage medical technology company focused on minimally-invasive bronchoscopic treatments for severe emphysema, centered on the Zephyr Valve System. The Zephyr Valve is placed via bronchoscopy with no incisions and has randomized-trial data showing improvements in pulmonary function, exercise capacity, breathlessness, and quality of life; it holds FDA breakthrough designation and received FDA premarket approval in June 2018. The Pulmonx solution also includes the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform to identify suitable patients. The company reports physicians in more than 25 countries have used over 76,000 valves to treat more than 19,000 patients, and Zephyr Valves are included in national and global treatment guidelines such as NICE and GOLD. Pulmonx is planning further clinical trials of AeriSeal, a foam-based bronchoscopic lung sealant for patients who cannot be treated with the Zephyr Valve. To support continued commercial expansion and R&D, Pulmonx announced a $66 million financing and secured an additional $17 million in growth capital to refinance existing debt. Pulmonx develops diagnostic and therapeutic pulmonary device technologies, with its core product the Zephyr® Valve for bronchoscopic lung volume reduction in severe emphysema/COPD. The Zephyr Valve is placed in a single bronchoscopic procedure with no incision and has been shown to improve quality of life, reduce shortness of breath, and increase activity. The device received expedited FDA approval as a breakthrough technology and is included in emphysema treatment guidelines from organizations such as GOLD and NICE. Since 2007, more than 15,000 patients have been treated with the Zephyr Valve worldwide. Pulmonx says it is well-positioned to lead the emerging global field of interventional pulmonology, and recent hires are intended to strengthen strategic and operational capabilities. Financially, the company has just closed an oversubscribed $65 million equity financing to support its growth. Pulmonx is a Redwood City, California and Neuchatel, Switzerland-based developer of minimally invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders. Led by interim CEO Oern Stuge, M.D., the company develops and markets the Chartis System and the Zephyr endobronchial valve (EBV), a diagnostic and therapeutic solution for emphysema-induced hyperinflation. The Zephyr therapy involves bronchoscopic placement of one-way valves to reduce hyperinflation in diseased portions of the lungs, thereby improving function of healthier lung regions. The Zephyr device received the CE Mark in 2003 and is in an investigational phase in the United States. Pulmonx closed a $20M senior secured term loan with Oxford Finance and intends to use the proceeds to support the U.S. clinical trial of its Zephyr EBV and to expand its business worldwide. Pulmonx develops and markets minimally-invasive devices for diagnosing and treating pulmonary disorders, including the Zephyr Endobronchial Valve (EBV) and the Chartis Pulmonary Assessment System. The company recently secured a $32M equity financing to support its next stage of growth. Both the Zephyr EBV and the Chartis system are CE marked and cleared for sale in Europe and other major international markets. Pulmonx plans to use the proceeds to support the international commercial launch of those products. The financing will also fund expansion of its commercial operations with the goal of reaching positive cash flow and profitability. In conjunction with the round, two investors will join the board of directors to support commercialization efforts. Pulmonx develops medical devices to treat emphysema by inserting a valve into the lung to shut off the diseased portion. The company is using the recent financing to create and advance its emphysema treatment devices. Pulmonx is based in Palo Alto, California, and was founded in 1998. It has previously raised $27 million. The latest financing consists of $3 million in convertible promissory notes. Investors in this round have not been disclosed.

No current team members are available.